To Evaluate The Lipid Lowing Effects And The Clinical Safety Of Intensive Therapy Of Chinese Medicine Zhibitai In Patients With Moderate And High Risk Of Atherosclerosis

Objective: To evaluate the lipid lowing effects and the clinical safety of intensive therapy of Chinese medicine Zhibitai in patients with moderate and high risk of atherosclerosis.Methods: 240 patients who were 55-72 year-old with moderate and high risk of atherosclerosis in our hospital from June 2007 to May 2008 were recruited. There were 157 male and 83 female among them. All the patients were randomly divided in to test group which was 120 people (79 male, 41 female) or control group which was 120 people (78 male, 42 female). Test group was received basic treatment plus 480mg of Zhibitai orally twice a day, whereas the control group was received basic treatment plus 10mg atorvastatin orally once daily (basic treatment means that conventional drug treatment: anti-platelet drug,nitrates agents,antihypertensive drugs and hypoglycemic agents in addition to lipid-lowering drugs). Blood lipoproteins, myocardial enzyme,liver and renal function were measured before treatment and at the fourth and eighth weeks after therapy , whereas hs-CRP,P-selectin,MMP-9,SIC AM-1 were detected before treatment and eighth week after therapy in all patients.Results: TC,TG and LDL-C were significantly decreased but HDL was increased in both group individually after 4 and 8 weeks treatment(p<0.01). Inflammatory factors such as hs- CRP,P-selectin,MMP-9,SICAM-1 were decreased significantly. However there was no significant difference between the two groups. There were no difference in liver and kidney function, myocardial enzyme, incidence of muscle-ache and digestive system reaction.Conclusion: Besides the lipoprotein disorder, the inflammatory factors in patients with moderate and high risk of atherosclerosis could be regulated by intensive therapy of Zhibitai. Most importantly, it is safe to use Zhibitai in clinic.